Abufaraj and coworkers recently reported that, in patients with metastatic PCa, GnRH antagonists are associated with lower overall mortality rate (but without a significant difference in PSA progression) and cardiovascular events compared with GnRH agonists, while inducing higher injection site reactions [123]. The gene discussed is GNRH1; the disease is posterior cortical atrophy.